Enliven Therapeutics(US:ELVN)2025-11-12 21:10Financial Performance - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $477.6 million, providing a cash runway into the first half of 2029[9] - Research and development (R&D) expenses for Q3 2025 were $18.2 million, a decrease of 14.4% from $21.3 million in Q3 2024[9] - General and administrative (G&A) expenses for Q3 2025 were $6.9 million, an increase of 18.2% from $5.8 million in Q3 2024[9] - The company reported a net loss of $20.1 million for Q3 2025, compared to a net loss of $23.2 million for Q3 2024, reflecting a 13.4% improvement[9] - Total operating expenses for Q3 2025 were $25.1 million, a decrease from $27.1 million in Q3 2024[17] - The company had a weighted-average of 62,094 shares outstanding for Q3 2025, compared to 48,267 shares for Q3 2024[17] Clinical Trials and Research - The ENABLE trial of ELVN-001 in CML has completed the randomized Phase 1b portion and is on track to initiate a Phase 3 pivotal trial in 2026[3][4] - ELVN-001 is designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML)[4][10] - The company presented data from the ENABLE Phase 1a/1b clinical trial at multiple medical meetings, highlighting the strength of the data and the potential for ELVN-001[3][4] - The company plans to present additional data from the ENABLE trial at the 67th Annual American Society of Hematology (ASH) meeting in December 2025[5]